IKZF2

Across TCGA pan-cancer cohorts, IKZF2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated IKZF2 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher IKZF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IKZF2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRC, BLCA, and ESCA are the cancer types where IKZF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.172	0.805	.001	24	view →
BLCA	OS	Median	IV	0.140	0.604	<.001	12	view →
ESCA	OS	Median	All	0.095	0.701	<.001	12	view →
OV	DFS	Median	All	0.132	0.541	.018	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	1.000	0.227	.011	5	view →
SARC	DFS	Median	All	0.179	0.594	.031	3	view →
LUAD	DFS	Median	All	0.559	0.814	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

IKZF2–KIRC (OS)

Open the KIRC breakdown →